Early Cancer Detection
Proven ability to detect all stages of canine lymphosarcoma and hemangiosarcoma.
High Detection Rate
Detects 76% of systemic canine cancers at 97% specificity.
Small Sample Size
Only 50 uL of EDTA-plasma needed for all canine breeds and sizes.
Accessible and Affordable
Now cancer screening is easily available at an affordable cost for you and your clients.
State of the Art Technology
Measures levels of nucleosomes circulating in the patient’s blood.
Peer Reviewed Evidence
Methodology backed by studies on canine lymphoma, canine hemangiosarcoma, and other common canine cancers.
Stop overpaying for in-clinic blood testing and analysis.
Heska’s Reset program provides veterinarians with accurate, better and faster blood testing and analysis at 35% less cost than with other competitive in-house diagnostic laboratory services.
The Nu.Q® Canine Cancer Screen and Monitor measures nucleosomes to provide clinicians with actionable results.
Effective Cancer Screening
Nucleosome measurement provides clinicians reasonable levels of suspicion for active neoplasia.
Early Detection, Earlier Treatment
Early detection leads to more comprehensive and effective treatment for your patient.
Easy To Use Test Cartridges
Room temperature storage, fully contained test cartridges return results in under 10 minutes.
After ongoing frustration with our previous blood analyser setup, we changed over to Heska when we were given an offer too good to refuse. We had some minor teeting problems with the CBC but the response by Heska was truly impressive and the problem was sorted in no time. We now know that any problems will be addressed promptly and efficiently, and the equipment has functioned faultlessly since.
Alcorn Street Vet
Technical Details & Downloads
Canine Cancer Screening in Your Practice
Early cancer detection can mean better treatment and outcomes for your patients. Studies in the United States show approximately 6 million dogs are diagnosed with cancer each year, with around 50% of dogs over 10 likely to develop cancer. These diagnoses are often unexpected and debilitating for patients and pet owners alike. In partnership with Volition Veterinary, Heska is proud to offer the Nu.Q® Canine Cancer Screen and Monitor. Cancer screening with the Nu.Q® Canine Cancer Screen and Monitor aids in early detection, leading to more comprehensive and effective treatment.
Cancer screening with Nu.Q® provides the opportunity to detect cancer early. Studies have shown that measuring nucleosomes in blood has the potential to detect multiple stages of common canine cancers, such as lymphoma and hemangiosarcoma.
Intended for screening dogs 7 years and older, or predisposed individuals and breeds, Nu.Q® Canine Cancer Screen and Monitor allows veterinary professionals the chance to catch cancer early and provide a higher level of care.
How Does it Work?
During cell death, chromatin is fragmented into nucleosomes, which are released into the bloodstream. Cancer is usually characterized by high levels of cellular turnover, in turn leading to higher levels of nucleosomes circulating in blood. The Nu.Q® Canine Cancer Screen and Monitor measures these nucleosomes to provide clinicians with actionable results.
- 77% of Canine Lymphosarcoma Found – detection of all 5 stages
- 82% of Canine Hemangiosarcoma Found – detection of all 3 stages
- Multi-cancer Study Results: Nu.Q Canine Cancer Screen and Monitor detects 76% of Systemic Cancers at 97% Specificity
Heska Support Teams are Here for You
We’re Available When You Need Us
Rest assured that when you need help, have questions, or have difficulties, we have you covered.
- Available 9:00am – 5:00pm AEST Daily
- Emergency Support During Off-Hours